Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Budesonide Inhaler Market?

In recent times, there has been substantial growth in the market size of budesonide inhalers. The market is set to expand from $6.37 billion in 2024 to $6.94 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.0%. This growth during the historic period is linked to the increased awareness about inhalation therapies, the growing preference for corticosteroid treatments, higher levels of air pollution leading to respiratory problems, the surging demand for minimally invasive methods of drug delivery, and the heightened focus on home healthcare solutions.

What Growth Rate Is Forecasted for the Budesonide Inhaler Market by 2029?

The market for budesonide inhalers is projected to experience robust growth in the coming years, reaching $9.68 billion in 2029 with a CAGR of 8.7%. The upward trend during the forecast period can be ascribed to the rise in funding for respiratory drug research, increased demand for individualized treatments in respiratory care, growing utilization of telemedicine and electronic prescribing, heightened cognizance of early detection and therapy, and escalating preference for combined inhaler treatments. Key trends during the outlook period include the advancement of improved drug delivery methods, the innovation in smart inhalers featuring digital tracking, the incorporation of AI and IoT in managing respiratory health, development in patient-oriented drug formatting, and the use of mobile applications for tracking adherence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24181&type=smp

Which Key Companies Are Shaping the Future of the Budesonide Inhaler Market?

Major companies operating in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.

Which Factors Are Driving Demand in the Budesonide Inhaler Industry?

The increasing number of respiratory ailments is anticipated to boost the expansion of the budesonide inhaler market in the future. Breathing struggles, along with symptoms like coughing, wheezing, and shortness of breath, characterize these medical conditions that affect the lungs and airways. They encompass conditions like asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung infections. Due to escalating air pollution, which increases interaction with harmful pollutants aggravating airways and deteriorating lung functionality, respiratory disorders are mainly on the rise. To support long-term control of respiratory conditions, budesonide inhalers deliver anti-inflammatory drugs directly to the lungs. These inhalers, due to their compactness, are simple to operate and carry, which helps minimize flare-ups and enhance respiratory wellness. For example, the Australian Bureau of Statistics, a government agency based in Australia, reported in December 2023 that the prevalence of COPD escalated from 2.4% in 2021 to 2.5% in 2022. Consequently, the surging occurrence of respiratory ailments is pushing the growth of the budesonide inhaler market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24181&type=smp

How Is the Budesonide Inhaler Market Segmented by Several Divisions?

The budesonide inhaler market covered in this report is segmented –

1) By Product Type: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Combination Inhalers

2) By Dosage Form: Aerosols, Dry Powder, Suspension, Spray

3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis

4) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Pharmacies

Subsegments:

1) Metered-Dose Inhalers: Pressurized Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Compatible Metered-Dose Inhalers, Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers

2) Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Capsule-Based Dry Powder Inhalers, Reservoir-Based Dry Powder Inhalers

3) Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Homecare Nebulizers, Hospital-Use Nebulizers

4) Combination Inhalers: Budesonide And Formoterol Inhalers, Budesonide And Salmeterol Inhalers, Budesonide, Glycopyrrolate, And Formoterol Inhalers, Budesonide And Vilanterol Inhalers

What are the Emerging Market Trends Driving the Growth of the Budesonide Inhaler Industry?

Prominent organizations in the budesonide inhaler market are concentrating their efforts on innovative product development, including generic offerings, to enhance affordability and accessibility for respiratory disease treatments. Generic inhaled medications are non-branded products that provide the same active ingredients, dosage, and therapeutic effectiveness as their named brand equivalents, usually at a reduced price. For example, in July 2023, the US pharmaceutical company Viatris Inc. partnered with the US-based pharmaceutical manufacturer Kindeva Drug Delivery L.P. to release Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol. This is the first generic version of Symbicort approved by the US federal agency, The Food and Drug Administration (FDA). The drug-device mix works to treat asthma and chronic obstructive pulmonary disease (COPD) by reducing airway inflammation through budesonide and relaxing the muscles around the airways with formoterol. This delivers a more cost-effective alternative for patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/budesonide-inhaler-global-market-report

Which Regions Are Driving Growth in the Budesonide Inhaler Market?

North America was the largest region in the budesonide inhaler market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the budesonide inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24181&type=smp

This Report Delivers Insight On:

1. How big is the budesonide inhaler market, and how is it changing globally?

2. Who are the major companies in the budesonide inhaler market, and how are they performing?

3. What are the key opportunities and risks in the budesonide inhaler market right now?

4. Which products or customer segments are growing the most in the budesonide inhaler market?

5. What factors are helping or slowing down the growth of the budesonide inhaler market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model